Core Viewpoint - Hepion Pharmaceuticals has successfully transitioned to the OTCQB Venture Market, with its common stock trading under the symbol HEPA starting June 25, 2025 [1]. Company Overview - Hepion Pharmaceuticals is a clinical stage biopharmaceutical company focused on developing and commercializing diagnostic tests for various conditions, including celiac disease, respiratory multiplex (Covid/Influenza A/B and RSV), helicobacter pylori (H. pylori), and hepatocellular carcinoma (HCC) [2].